Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company dedicated to pioneering novel cancer therapies and improving lives. As leaders in XPO1 inhibition, they target multiple high unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL.
